The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Therapeutic Fc Fusion Protein Market Research Report 2024
Synopsis
Fc-fusion proteins are bioengineered polypeptides that join the crystallizable fragment (Fc) domain of an antibody with another biologically active protein domain or peptide to generate a molecule with unique structure–function properties and significant therapeutic potential. The gamma immunoglobulin (IgG) isotype is often used as the basis for generating Fc-fusion proteins
Global Therapeutic Fc Fusion Protein market is projected to reach US$ 66380 million in 2029, increasing from US$ 32780 million in 2022, with the CAGR of 10.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Therapeutic Fc Fusion Protein market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Therapeutic Fc Fusion Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
Bristol-Myers Squibb
Regeneron
Bayer
Amgen
Pfizer
Eli Lilly and Company
Sobi
Kanghong Pharma
3SBIO
Celgen Biopharma
Segment by Type
Brands Drugs
Biosimilar Drugs
Segment by Application
Autoimmune Disease
Eye Diseases
Diabetes
Hemophilia
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Therapeutic Fc Fusion Protein report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Fc-fusion proteins are bioengineered polypeptides that join the crystallizable fragment (Fc) domain of an antibody with another biologically active protein domain or peptide to generate a molecule with unique structure–function properties and significant therapeutic potential. The gamma immunoglobulin (IgG) isotype is often used as the basis for generating Fc-fusion proteins
Global Therapeutic Fc Fusion Protein market is projected to reach US$ 66380 million in 2029, increasing from US$ 32780 million in 2022, with the CAGR of 10.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Therapeutic Fc Fusion Protein market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Therapeutic Fc Fusion Protein market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
Bristol-Myers Squibb
Regeneron
Bayer
Amgen
Pfizer
Eli Lilly and Company
Sobi
Kanghong Pharma
3SBIO
Celgen Biopharma
Segment by Type
Brands Drugs
Biosimilar Drugs
Segment by Application
Autoimmune Disease
Eye Diseases
Diabetes
Hemophilia
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Therapeutic Fc Fusion Protein report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Therapeutic Fc Fusion Protein Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Brands Drugs
1.2.3 Biosimilar Drugs
1.3 Market by Application
1.3.1 Global Therapeutic Fc Fusion Protein Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Autoimmune Disease
1.3.3 Eye Diseases
1.3.4 Diabetes
1.3.5 Hemophilia
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Therapeutic Fc Fusion Protein Market Perspective (2018-2029)
2.2 Therapeutic Fc Fusion Protein Growth Trends by Region
2.2.1 Global Therapeutic Fc Fusion Protein Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Therapeutic Fc Fusion Protein Historic Market Size by Region (2018-2023)
2.2.3 Therapeutic Fc Fusion Protein Forecasted Market Size by Region (2024-2029)
2.3 Therapeutic Fc Fusion Protein Market Dynamics
2.3.1 Therapeutic Fc Fusion Protein Industry Trends
2.3.2 Therapeutic Fc Fusion Protein Market Drivers
2.3.3 Therapeutic Fc Fusion Protein Market Challenges
2.3.4 Therapeutic Fc Fusion Protein Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Therapeutic Fc Fusion Protein Players by Revenue
3.1.1 Global Top Therapeutic Fc Fusion Protein Players by Revenue (2018-2023)
3.1.2 Global Therapeutic Fc Fusion Protein Revenue Market Share by Players (2018-2023)
3.2 Global Therapeutic Fc Fusion Protein Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Therapeutic Fc Fusion Protein Revenue
3.4 Global Therapeutic Fc Fusion Protein Market Concentration Ratio
3.4.1 Global Therapeutic Fc Fusion Protein Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Therapeutic Fc Fusion Protein Revenue in 2022
3.5 Therapeutic Fc Fusion Protein Key Players Head office and Area Served
3.6 Key Players Therapeutic Fc Fusion Protein Product Solution and Service
3.7 Date of Enter into Therapeutic Fc Fusion Protein Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Therapeutic Fc Fusion Protein Breakdown Data by Type
4.1 Global Therapeutic Fc Fusion Protein Historic Market Size by Type (2018-2023)
4.2 Global Therapeutic Fc Fusion Protein Forecasted Market Size by Type (2024-2029)
5 Therapeutic Fc Fusion Protein Breakdown Data by Application
5.1 Global Therapeutic Fc Fusion Protein Historic Market Size by Application (2018-2023)
5.2 Global Therapeutic Fc Fusion Protein Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Therapeutic Fc Fusion Protein Market Size (2018-2029)
6.2 North America Therapeutic Fc Fusion Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Therapeutic Fc Fusion Protein Market Size by Country (2018-2023)
6.4 North America Therapeutic Fc Fusion Protein Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Therapeutic Fc Fusion Protein Market Size (2018-2029)
7.2 Europe Therapeutic Fc Fusion Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Therapeutic Fc Fusion Protein Market Size by Country (2018-2023)
7.4 Europe Therapeutic Fc Fusion Protein Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Therapeutic Fc Fusion Protein Market Size (2018-2029)
8.2 Asia-Pacific Therapeutic Fc Fusion Protein Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Therapeutic Fc Fusion Protein Market Size by Region (2018-2023)
8.4 Asia-Pacific Therapeutic Fc Fusion Protein Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Therapeutic Fc Fusion Protein Market Size (2018-2029)
9.2 Latin America Therapeutic Fc Fusion Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Therapeutic Fc Fusion Protein Market Size by Country (2018-2023)
9.4 Latin America Therapeutic Fc Fusion Protein Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Therapeutic Fc Fusion Protein Market Size (2018-2029)
10.2 Middle East & Africa Therapeutic Fc Fusion Protein Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Therapeutic Fc Fusion Protein Market Size by Country (2018-2023)
10.4 Middle East & Africa Therapeutic Fc Fusion Protein Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Therapeutic Fc Fusion Protein Introduction
11.1.4 Sanofi Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Therapeutic Fc Fusion Protein Introduction
11.2.4 Bristol-Myers Squibb Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Regeneron
11.3.1 Regeneron Company Detail
11.3.2 Regeneron Business Overview
11.3.3 Regeneron Therapeutic Fc Fusion Protein Introduction
11.3.4 Regeneron Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.3.5 Regeneron Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Therapeutic Fc Fusion Protein Introduction
11.4.4 Bayer Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.4.5 Bayer Recent Development
11.5 Amgen
11.5.1 Amgen Company Detail
11.5.2 Amgen Business Overview
11.5.3 Amgen Therapeutic Fc Fusion Protein Introduction
11.5.4 Amgen Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.5.5 Amgen Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Therapeutic Fc Fusion Protein Introduction
11.6.4 Pfizer Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.6.5 Pfizer Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Therapeutic Fc Fusion Protein Introduction
11.7.4 Eli Lilly and Company Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.7.5 Eli Lilly and Company Recent Development
11.8 Sobi
11.8.1 Sobi Company Detail
11.8.2 Sobi Business Overview
11.8.3 Sobi Therapeutic Fc Fusion Protein Introduction
11.8.4 Sobi Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.8.5 Sobi Recent Development
11.9 Kanghong Pharma
11.9.1 Kanghong Pharma Company Detail
11.9.2 Kanghong Pharma Business Overview
11.9.3 Kanghong Pharma Therapeutic Fc Fusion Protein Introduction
11.9.4 Kanghong Pharma Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.9.5 Kanghong Pharma Recent Development
11.10 3SBIO
11.10.1 3SBIO Company Detail
11.10.2 3SBIO Business Overview
11.10.3 3SBIO Therapeutic Fc Fusion Protein Introduction
11.10.4 3SBIO Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.10.5 3SBIO Recent Development
11.11 Celgen Biopharma
11.11.1 Celgen Biopharma Company Detail
11.11.2 Celgen Biopharma Business Overview
11.11.3 Celgen Biopharma Therapeutic Fc Fusion Protein Introduction
11.11.4 Celgen Biopharma Revenue in Therapeutic Fc Fusion Protein Business (2018-2023)
11.11.5 Celgen Biopharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
